New Lipid-Based Oral Delivery System
ePT--the Electronic Newsletter of Pharmaceutical Technology
Vancouver, BC, Canada-Researchers from the University of British Columbia are developing a new method for delivering Amphotericin B, a potent antifungal agent for fatal blood-borne fungal infections that currently must be administered intravenously.
Vancouver, BC, Canada (March 5)-Researchers from the University of British Columbia (www.ubc.ca) are developing a new method for delivering Amphotericin B, a potent antifungal agent for fatal blood-borne fungal infections that currently must be administered intravenously. The liquid oral preparation incorporates drug molecules in a lipid-based formulation and reportedly triggers a different molecular interaction than that of the i.v. product.
Led by Kishor M. Wasan, pharmaceutical sciences professor, the research team discovered that the lipid-based system attacks fungal cells only while inhibiting the drug’s interaction with kidney cells; thereby boosting effectiveness and reducing toxicity.
The delivery system was tested in animal models to treat Candida albicans, and a clinical study involving 50–100 patients is planned for later this year.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
